In the wake of potential regulatory changes as well as ongoing concerns regarding access, affordability, and the sustainability of expenditures on drugs, this study aims to assess Canada’s timely availability of innovative therapies from global companies relative to comparable jurisdictions and explore the market and policy factors that impact launch sequencing of therapeutics to global markets.

The analysis uses recent data and information to understand launch sequencing of therapeutic prescription drugs in Canada in terms of total launches, launch lags, and the cumulative probability of launches in Canada relative to other comparable international jurisdictions.

The report also discusses how market and/or regulatory factors may influence launch decisions internationally and in Canada.

Comments